Kosan Biosciences, Inc.

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a true ‘go-to’ executive, Susan has been instrumental in growing this organization, which is now at the cusp of achieving its long-stated goal of being a fully integrated biopharmaceutical enterprise. To all of this, we now have the great fortune of adding Susan’s many strengths to our Board.” Ms. Kanaya has served as ChemoCentryx’s Executive Vice President, Chief Financial and Administrative Officer since October 2016 and as Secretary since February 2006. Prior to that she served as the Company’s Senior Vice President, Finance, and Chief Financial Officer. Before joining ChemoCentryx, Ms. Kanaya was the Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., including Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley. “I’m honored to be joining the ChemoCentryx Board of Directors and look forward to playing a larger role in driving our Company’s growth and supporting its strategic and operational direction,” said Ms. Kanaya. “We’re at a pivotal point in our evolution as we near our first commercial launch, and I look forward to these expanded responsibilities as we continue working toward delivering on our promise to patients, providers and shareholders.” About ChemoCentryx ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Forward-Looking Statements ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the Company’s goal of being a fully integrated biopharmaceutical enterprise, the achievement of anticipated goals and milestones, whether avacopan will be approved by the FDA or EMA for the treatment of ANCA-associated vasculitis, and whether the Company's drug candidates will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 1, 2021 and its other reports which are available from the SEC's website ( ) and on ChemoCentryx's website ( ) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Contacts: Susan M. Kanaya Executive Vice President, Chief Financial and Administrative Officer investor@chemocentryx.com Media: Stephanie Tomei 408.234.1279 media@chemocentryx.com Investors: Burns McClellan, Inc. Lee Roth 212.213.0006 lroth@burnsmc.com

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Boragen Inc., a world-leading boron-based discovery platform, today announced that it has added Dr. Brian Metcalf to its Scientific Advisory Board. Dr. Metcalf has held a number of executive management positions in the field of drug discovery and innovation; most recently he served as Chief Scientific Officer for Global Blood Therapeutics (GBT). Under Dr. Metcalf’s direction, GBT’s voxelotor (sold under the brand name Oxbryta®) was approved for sickle cell anemia in 2019. Earlier he served as Head of Drug Discovery at Incyte Pharmaceuticals. During his tenure at Incyte, the company was transformed from a genomics information company to one focused on drug discovery, culminating in the discovery of Jakafi®, a JAK1/2 kinase inhibitor. Jakafi was approved for the treatment of myelofibrosis in 2011. “There are many attractive applications of the Boragen platform in drug discovery,” said Dr. Metcalf upon joining the Scientific Advisory Board. Other positions Metcalf has held include the Chief Scientific Officer of Kosan Biosciences and several executive roles with SmithKline Beecham over the course of 17 years. Dr. Metcalf is also credited with the discovery of Sabril®, for epilepsy, and has numerous patents and publications in the drug discovery arena. Boragen’s Scientific Advisory board is comprised of distinguished scientists working toward discovery and development of boron-based platform technology for wide-ranging applications in agriculture, animal health, and human health. Members currently include Dr. Peter Hertl, former Head of Global Regulatory and Product Safety for Syngenta; Dr. Jake Plattner, former Sr. Vice President of Research for Anacor Pharmaceuticals; Dr. Robert Steffens, former Vice President of Product Development for Bayer; and Dr. Mark Zettler, an advisor and strategist for food and ag tech startups and investors. ABOUT BORAGEN Boragen, founded in 2015 by world-renowned experts in boron chemistry, is headquartered in Research Triangle Park, North Carolina. The company utilizes boron’s unique properties to design and develop novel solutions targeting needs in crop protection, animal health and human health. To date, the company has developed a unique boron-based screening library targeting diverse biological applications. For more information visit .

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that stockholders of Kosan Biosciences Incorporated (NASDAQ: KOSN) (“Kosan”) tendered approximately 41,449,606 shares, including 1,682,151 shares subject to guaranteed delivery procedures, representing about 97.1% of the shares outstanding. According to the terms of Bristol-Myers Squibb’s tender offer for all of the outstanding common stock of Kosan, shares that were validly tendered and not withdrawn have been accepted for payment. The tender offer expired at midnight EDT on June 25, 2008, and was not extended.